EICHORCondition: Parkinsons Disease · Sponsor: Hoffmann-La Roche
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Barrow Neurological Institute | Phoenix, Arizona, United States | — |
| Neurology Center of North Orange County | Fullerton, California, United States | — |
| UC San Diego | La Jolla, California, United States | — |
| Keck School of Medicine of USC | Los Angeles, California, United States | — |
| Cedars Sinai Medical Center | Los Angeles, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| CenExel Rocky Mountain Clinical Research, LLC | Englewood, Colorado, United States | — |
| Institute for Neurodegenerative Disorders | New Haven, Connecticut, United States | — |
| JEM Research LLC | Atlantis, Florida, United States | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton, Florida, United States | — |
| Renstar Medical Research | Ocala, Florida, United States | — |
+ 98 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04777331